Decentralized Clinical Trials

Memo

Decentralized clinical trials (DCT) have the potential to improve recruitment rates, simplify compliance, reduce drop-out rates, and speed-up your product’s time to market. Despite this, only a fraction of clinical trials are currently run as hybrid of virtual models. This is about to change. The age of decentralized clinical trials is here, and keeping pace with the rest of the industry means preparing your internal processes for the change. Join us online in December as DCT pioneers help you to develop the toolkit you need to join the DCT revolution. Prices:Conference + Breakfast Workshop (Industry Pricing): USD 1298.0,Conference Only (Industry Pricing) : USD 1199.0,Conference + Breakfast Workshop (Vendor Pricing) : USD 1799.0,Conference Only (Vendor Pricing) : USD 1898.0 Speakers: Rodrigo Garcia, Head of Clinical Innovation, EMD Serono, Jennifer Wulff, Director, Global Product Development, Pfizer, Amir Lahav, Executive Director and Head of Digital Medicine, Karyopharm Therapeutics, Richard Erwin, Sr Director of Operations, Addario Lung Cancer Medical Institute, Acacia Parks, Chief Science Officer, Happify, Gareth Powell, Business Development Officer, NIHR, Steven Cummings, Director and Research Scientist, University of California, San Francisco, Jimmy Bechtel, Director of Innovation and Engagement, Society for Clinical Research Sites, Alka Shaunik, Global Therapy Area Head Cardiovascular and Metabolism, Medical Affairs, CSL Behring, Tom Switzer, Digital Health Scientist, Genentech, Natalie Wilson, Business Development Manager, NIHR, Craig Lipset, Founder Clinical, Innovation Partners, Hassan Kadhim, Director, Head of Clinical Trial Business Capabilities, Bristol Myers Squibb, Kai Langel, Director, Clinical Innovation, Janssen, Esther Middleditch, International Clinical Program Leader, Roche, Joe Dustin, Head of Clinical Innovation, Bristol Myers Squibb, Rasmus Hogreffe, Former Head of Virtual Clinical Trials, Leo Innovation Lab Time: 9:00 am - 6:00 pm